Trials / Approved For Marketing
Approved For MarketingNCT00989807
Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
Expanded Access for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- —
Summary
This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aztreonam lysine | Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily |
Timeline
- First posted
- 2009-10-06
- Last updated
- 2012-12-13
Locations
4 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00989807. Inclusion in this directory is not an endorsement.